| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc. | TRUSELTIQ (infigratinib)- (PROOF 302) | Urothelial Carcinoma | Phase 3 | Ongoing | Oral | Oncology |
| BridgeBio Pharma Inc. | Infigratinib - (ACCEL) | Hypochondroplasia | Phase 2 | Ongoing | Oral | Genetic Disorder |
| BridgeBio Pharma Inc. | Encaleret - (RECLAIM-HP) | Chronic hypoparathyroidism | Phase 3 | Trial Planned | oral | Endocrinology |
| BridgeBio Pharma Inc. | PTR-01 | Recessive dystrophic epidermolysis bullosa (RDEB) | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| BridgeBio Pharma Inc. | TRUSELTIQ (infigratinib) | Recurrent Glioblastoma | Phase 2 | Ongoing | Oral | Oncology |
| Bright Minds Biosciences Inc. | BMB-101 - (BREAKTHROUGH) | Absence Epilepsy & Dravet Syndrome | Phase 2 | Data Released | Oral | Neurology |
| Bright Minds Biosciences Inc. | BMB-101 - (BREAKTHROUGH) | Absence Epilepsy & Dravet Syndrome | Phase 2 | Data Released | Oral | Neurology |
| Bristol-Myers Squibb Company | Neoadjuvant nivolumab (N) + chemotherapy - (CheckMate-816) | Non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |